Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.

HD

HDFC Pharma and Healthcare Fund - IDCW Option - Direct Plan

HDFC Mutual Fund · Equity · Sectoral/ Thematic

₹23.52

+0.1 (+0.44%)

AUM: —

NAV updated 1 day ago

Plan

Direct

Option

Idcw

Risk

Very High

Sharpe Ratio

1.84

Std Dev (1Y)

13.96%

Historical Returns (CAGR)

Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.

1m

+12.22%

3m

+6.35%

6m

+17.38%

1y

+31.59%

3y

+30.58%

5y

—

10y

—

since inception

+31.6%

TopFund's Take on HDFC Pharma and Healthcare Fund - IDCW Option - Direct Plan

HDFC Pharma and Healthcare Fund - IDCW Option - Direct Plan is a Sectoral/ Thematic fund from HDFC Mutual Fund.

Cost: Expense ratio data for this fund isn't available yet.

Risk-adjusted performance: Over the trailing 1-year period, the fund shows a strong Sharpe ratio of 1.84 — the fund has generated solid returns relative to the volatility it exposed investors to. Separately, annualised volatility of 13.96% is fairly typical for Sectoral/ Thematic funds.

Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.

This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.

Sector Allocation

Sector allocation not available yet.

Asset Allocation

Asset allocation not available yet.

Frequently Asked Questions about HDFC Pharma and Healthcare Fund - IDCW Option - Direct Plan

* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

No comments yet — start the discussion.